These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 29440868)

  • 1. Ocular comfort assessment of lifitegrast ophthalmic solution 5.0% in OPUS-3, a Phase III randomized controlled trial.
    Nichols KK; Holland E; Toyos MM; Peace JH; Majmudar P; Raychaudhuri A; Hamdani M; Roy M; Shojaei A
    Clin Ophthalmol; 2018; 12():263-270. PubMed ID: 29440868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study.
    Tauber J; Karpecki P; Latkany R; Luchs J; Martel J; Sall K; Raychaudhuri A; Smith V; Semba CP;
    Ophthalmology; 2015 Dec; 122(12):2423-31. PubMed ID: 26365210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and tolerability of lifitegrast ophthalmic solution 5.0%: Pooled analysis of five randomized controlled trials in dry eye disease.
    Nichols KK; Donnenfeld ED; Karpecki PM; Hovanesian JA; Raychaudhuri A; Shojaei A; Zhang S
    Eur J Ophthalmol; 2019 Jul; 29(4):394-401. PubMed ID: 30112930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3).
    Holland EJ; Luchs J; Karpecki PM; Nichols KK; Jackson MA; Sall K; Tauber J; Roy M; Raychaudhuri A; Shojaei A
    Ophthalmology; 2017 Jan; 124(1):53-60. PubMed ID: 28079022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of Lifitegrast Ophthalmic Solution 5.0% in Patients With Dry Eye Disease: A 1-Year, Multicenter, Randomized, Placebo-Controlled Study.
    Donnenfeld ED; Karpecki PM; Majmudar PA; Nichols KK; Raychaudhuri A; Roy M; Semba CP
    Cornea; 2016 Jun; 35(6):741-8. PubMed ID: 27055211
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lifitegrast clinical efficacy for treatment of signs and symptoms of dry eye disease across three randomized controlled trials.
    Holland EJ; Whitley WO; Sall K; Lane SS; Raychaudhuri A; Zhang SY; Shojaei A
    Curr Med Res Opin; 2016 Oct; 32(10):1759-1765. PubMed ID: 27388660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study.
    Sheppard JD; Torkildsen GL; Lonsdale JD; D'Ambrosio FA; McLaurin EB; Eiferman RA; Kennedy KS; Semba CP;
    Ophthalmology; 2014 Feb; 121(2):475-83. PubMed ID: 24289915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Lifitegrast Ophthalmic Solution, 5.0%, in Patients With Moderate to Severe Dry Eye Disease: A Post Hoc Analysis of 2 Randomized Clinical Trials.
    Holland EJ; Jackson MA; Donnenfeld E; Piccolo R; Cohen A; Barabino S; Rolando M; Figueiredo FC
    JAMA Ophthalmol; 2021 Nov; 139(11):1200-1208. PubMed ID: 34617974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lifitegrast Ophthalmic Solution 5% Is a Safe and Efficient Eyedrop for Dry Eye Disease: A Systematic Review and Meta-Analysis.
    Li JX; Tsai YY; Lai CT; Li YL; Wu YH; Chiang CC
    J Clin Med; 2022 Aug; 11(17):. PubMed ID: 36078948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lifitegrast ophthalmic solution in the treatment of signs and symptoms of dry eye disease: design, development, and place in therapy.
    Godin MR; Gupta PK
    Clin Ophthalmol; 2017; 11():951-957. PubMed ID: 28579745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Matching-adjusted indirect comparison of phase 3 clinical trial outcomes of OC-01 (varenicline solution) nasal spray and lifitegrast 5% ophthalmic solution for the treatment of dry eye disease.
    White DE; Hendrix LH; Sun L; Tam I; Macsai M; Gibson AA
    J Manag Care Spec Pharm; 2023 Jan; 29(1):69-79. PubMed ID: 36030415
    [No Abstract]   [Full Text] [Related]  

  • 12. A Post-Acute Ocular Tolerability Comparison of Topical Reproxalap 0.25% and Lifitegrast 5% in Patients with Dry Eye Disease.
    McMullin D; Clark D; Cavanagh B; Karpecki P; Brady TC
    Clin Ophthalmol; 2021; 15():3889-3900. PubMed ID: 34588761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the clinical efficacy and comfort of olopatadine hydrochloride 0.1% ophthalmic solution and nedocromil sodium 2% ophthalmic solution in the human conjunctival allergen challenge model.
    Butrus S; Greiner JV; Discepola M; Finegold I
    Clin Ther; 2000 Dec; 22(12):1462-72. PubMed ID: 11192137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lifitegrast Ophthalmic Solution 5%: A Review in Dry Eye Disease.
    Keating GM
    Drugs; 2017 Feb; 77(2):201-208. PubMed ID: 28058622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase 2 randomized, double-masked, placebo-controlled study of novel nonsystemic kinase inhibitor TOP1630 for the treatment of dry eye disease.
    Taylor M; Ousler G; Torkildsen G; Walshe C; Fyfe MCT; Rowley A; Webber S; Sheppard JD; Duggal A
    Clin Ophthalmol; 2019; 13():261-275. PubMed ID: 30858682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy, safety, and tolerability of lifitegrast 5% eye drops: A randomized, double-blind, active-controlled trial in Indian patients with dry eye disease.
    Sharma N; Basu S; Shetty R; Kumar P; Mondal A; Babu PS; Srivastava R; Pande RA; Karat S; Desai HP; Manjula S; Kumar M K
    Indian J Ophthalmol; 2024 Aug; ():. PubMed ID: 39141509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A placebo-controlled comparison of ketotifen fumarate and nedocromil sodium ophthalmic solutions for the prevention of ocular itching with the conjunctival allergen challenge model.
    Greiner JV; Minno G
    Clin Ther; 2003 Jul; 25(7):1988-2005. PubMed ID: 12946546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erratum: Ocular comfort assessment of lifitegrast ophthalmic solution 5.0% in OPUS-3, a Phase III randomized controlled trial [Corrigendum].
    Clin Ophthalmol; 2018; 12():913. PubMed ID: 29845978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized, double-masked comparison of olopatadine ophthalmic solution, mometasone furoate monohydrate nasal spray, and fexofenadine hydrochloride tablets using the conjunctival and nasal allergen challenge models.
    Spangler DL; Abelson MB; Ober A; Gotnes PJ
    Clin Ther; 2003 Aug; 25(8):2245-67. PubMed ID: 14512132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children.
    Abelson MB; Torkildsen GL; Williams JI; Gow JA; Gomes PJ; McNamara TR;
    Clin Ther; 2009 Sep; 31(9):1908-21. PubMed ID: 19843481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.